IMIDAZODIAZEPINE COMPOUND Russian patent published in 2020 - IPC C07D487/04 A61K31/551 A61P25/14 A61P25/16 A61P25/18 A61P25/28 A61P25/36 A61P43/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound selected from a group consisting of 4-fluoro-3-(2-oxo-2-{2-[4-(trifluoromethyl)phenyl]-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-yl}ethyl)-1,3-benzoxazole-2(3H)-one, 4-fluoro-3-{2-[2-(2-fluorophenyl)-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-yl]-2-oxoethyl}-1,3-benzoxazole-2(3H)-one, 3-[2-(4,5-dihydro-1H-[1,4]diazepino[1,2-a]benzimidazole-2(3H)-yl)-2-oxoethyl]-4,5-difluoro-1,3-benzoxazole-2(3H)-one, 4-fluoro-3-[2-(8-fluoro-4,5-dihydro-1H-[1,4]diazepino[1,2-a]benzimidazole-2(3H)-yl)-2-oxoethyl]-1,3-benzoxazole-2(3H)-one, 4,5-difluoro-3-[2-oxo-2-(2-phenyl-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-yl)ethyl]-1,3-benzoxazole-2(3H)-one, 4-fluoro-3-{2-[2-(3-fluorophenyl)-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-yl]-2-oxoethyl}-1,3-benzoxazole-2(3H)-one and 3-{2-[2-(4-chlorophenyl)-6,7-dihydro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-yl]-2-oxoethyl}-4-fluoro-1,3-benzoxazole-2(3H)-one, or a pharmaceutically acceptable salt thereof. Invention also relates to a pharmaceutical composition which is a positive allosteric modulator of a dopamine D1 receptor containing a compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

EFFECT: compound or its pharmaceutically acceptable salt according to the invention for prevention and/or treatment of negative symptoms of schizophrenia, cognitive impairment associated with schizophrenia (CIAS), Parkinson's disease or Huntington's disease.

10 cl, 12 tbl, 14 ex